Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
262 hedge funds and large institutions have $3.97B invested in Sage Therapeutics in 2021 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 79 increasing their positions, 88 reducing their positions, and 39 closing their positions.
38% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 39
6% more funds holding
Funds holding: 248 → 262 (+14)
10% less repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 88
12.43% less ownership
Funds ownership: 103.37% → 90.94% (-12%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
15% less capital invested
Capital invested by funds: $4.65B → $3.97B (-$680M)
49% less call options, than puts
Call options by funds: $48.7M | Put options by funds: $96.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$77.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$72.3M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$66.5M |
| 4 |
BlackRock
New York
|
+$32.9M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$27.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$57.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$38.4M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$38.2M |
| 4 |
PA
Perceptive Advisors
New York
|
-$38.1M |
| 5 |
JP Morgan Chase
New York
|
-$30.9M |
SAGE Hedge Fund Activity: Q1 2021 in Review
262 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2021, worth a combined $3.97B — down 15% from $4.65B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new SAGE positions and 39 closed out — a net gain of 15 holders — while 79 added to existing stakes and 88 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $77.9M. The largest seller was Farallon Capital Management, cutting an estimated $57.8M.
- 262 institutional investors held Sage Therapeutics (SAGE) as of Q1 2021, up from 248 in Q4 2020.
- Funds reported $3.97B of Sage Therapeutics stock for Q1 2021, down 15% quarter-over-quarter.
- 54 funds opened new Sage Therapeutics positions in Q1 2021 and 39 closed out, a net change of +15 holders.
- The largest Sage Therapeutics buyer in Q1 2021 was Fidelity Investments, an estimated $77.9M added.
- The largest Sage Therapeutics seller in Q1 2021 was Farallon Capital Management, an estimated $57.8M sold.
Based on aggregated 13F filings for Q1 2021.